Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view

• Published in: Clinical rheumatology 2015-04, Vol.34 (4), p.635-640
• Main Authors: Pineda, Carlos, Caballero-Uribe, Carlo V., de Oliveira, Marcia Gonclaves, Lipszyc, Pedro Saul, Lopez, Jose Julian, Mataos Moreira, Marcelo Mario, Azevedo, Valderilio Feijo
• Format: Article
• Language: English
• Subjects: Biological Products; Biosimilar Pharmaceuticals - chemistry; Biosimilar Pharmaceuticals - standards; Biosimilar Pharmaceuticals - therapeutic use; Humans; Latin America; Medicine; Medicine & Public Health; Patient Safety; Pharmacovigilance; Practice Guidelines as Topic; Review; Review Article; Rheumatology; Technology, Pharmaceutical - methods; Therapeutic Equivalency
• ISSN: 0770-3198; 1434-9949
• DOI: 10.1007/s10067-015-2887-0

The use of biotechnology-derived medicines has significantly increased in recent decades. Although biosimilars undergo rigorous characterization as well as clinical studies to document their safety and effectiveness, they are highly complex molecules and small changes in the purification and production process of a biosimilar can have major implications in its safety and effectiveness profile. In Latin America, regulatory authorities have begun to establish well-described and standardized pathways that permit a biosimilar to gain commercial licensure. In order to be certain that a biosimilar reaches its potential in ordinary clinical use, an intensive post-licensing monitoring system must be established since it is the only means to ascertain the true similarity between the original biologic and its biosimilar. Pharmacovigilance allows national authorities to determine a drug’s performance in the marketplace. An effective tracking and pharmacovigilance system for biological medicines has many steps and processes. To aid policy makers in Latin American in addressing the many issues surrounding the establishment of an effective pharmacovigilance system, the Americas Health Foundation convened a group of experts to discuss the topic and develop recommendations for implementation. The group discussed current challenges and gaps in pharmacovigilance in Latin America, paying close attention to the major issues associated with traceability and pharmacovigilance of biosimilars following their approval. The recommendations developed should enable countries to accurately document the safety and performance of a biosimilar as experienced by patients under real-life conditions and have a significant impact on the successful implementation of pharmacovigilance of biosimilars throughout the region.